Day: February 12, 2025

Form 8.3 – [ALLIANCE PHARMA PLC – 11 02 2025] – (CGWL)

Written by Customer Service on February 12, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ALLIANCE PHARMA PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Written by Customer Service on February 12, 2025. Posted in Dividend Reports And Estimates.

Generated Record Quarterly Revenue of $85 Million, a 35% Annual Increase DALLAS, Feb. 12, 2025 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX) (the “Company”), a leading private markets solutions provider, today reported financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsRevenue: $85 million, a 35% increase year over year. Fee-Related Revenue: $85 million, a 37% increase year over year. Fee-Paying Assets Under Management: $25.7 billion, a 10% increase year over year. GAAP Net Income (Loss): $5.7 million compared to $(1.9) million in the prior year. Adjusted EBITDA: $42.9 million, a 40% increase year over year. Fee-Related Earnings: $42.7 million, a 39% increase year over year. Adjusted Net Income: $35.3 million, a 39% increase year over year. Fully Diluted GAAP EPS: $0.05...

Aeries Technology Announces Strategic Leadership Changes to Strengthen Market Leadership and AI-Driven Operational Excellence

Written by Customer Service on February 12, 2025. Posted in Public Companies.

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) — Aeries Technology, Inc. (“Aeries” or “the Company”) (Nasdaq: AERT), a leading provider of global capability center (GCC) solutions, today announced a strategic leadership realignment to drive sustainable growth and strengthen its market position. As part of these changes, Ajay Khare, a founding partner of Aeries, has been appointed Chief Executive Officer, succeeding Sudhir Panikassery, who transitions to Non-Executive Vice Chairman on the Board. A key architect of Aeries’ growth since its inception, Ajay has played a pivotal role in shaping the company’s strategy, previously serving as Chief Revenue Officer and Chief Operating Officer. With a unique blend of operational expertise and commercial acumen, his extensive experience partnering with private equity firms and their portfolio companies...

Apollo Funds Acquire Bold Production Services, a Leading Provider of Production-Linked Contracted Gas Treatment Solutions

Written by Customer Service on February 12, 2025. Posted in Mergers And Acquisitions.

Transaction to Further Accelerate Bold’s Growth Amid Increasing Demand for U.S. Natural Gas and Required Treatment Solutions HOUSTON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE:APO), today announced that funds managed by Apollo affiliates (the “Apollo Funds”) have acquired a majority interest in Bold Production Services, LLC (“Bold” or the “Company”), a provider of production-linked, contracted natural gas treatment solutions that enable the downstream use of natural gas, while reducing excess emissions and waste through proprietary equipment design. Founded in 2013, Bold’s fleet of 700+ owned assets, including dehydration units, H2S treating units and total flow coolers, serves a blue-chip customer base across the Permian and Eagle Ford basins. The investment from the Apollo Funds will support Bold’s continued...

Conduent Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on February 12, 2025. Posted in Earnings Releases And Operating Results.

Key Q4 and Full Year 2024 HighlightsRevenue: Q4 $800M / FY $3,356M Adj. Revenue(1): Q4 $800M / FY $3,176M Pre-tax Income (Loss): Q4 $(82)M / FY $504M Adj. EBITDA Margin(1): Q4 4.0% / FY 3.9% New Business Signings ACV(2): Q4 $137M / FY $485M Net ARR Activity Metric(2) (TTM): $92MFLORHAM PARK, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a global technology-led business process solutions and services company, today announced its fourth quarter and full year 2024 financial results. Cliff Skelton, Conduent President and Chief Executive Officer stated, “2024 proved to be broadly in line with what we planned for. It was a year we said would be characterized by a continued shift to growth, with a focus on new leadership, a rationalized portfolio, improved industry recognition, and improved client retention....

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time

Written by Customer Service on February 12, 2025. Posted in Earnings Releases And Operating Results.

BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About Lantheus Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to...

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on February 12, 2025. Posted in Earnings Releases And Operating Results.

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) plus nivolumab in advanced melanoma is enrollingEnrolled first patients in trials evaluating RP2 for the treatment of metastatic uveal melanoma and hepatocellular carcinomaWOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2024 and provided a business update. “Over the past couple of months, we have achieved significant regulatory milestones for RP1...

QXO Receives Antitrust Clearance for Acquisition of Beacon Roofing Supply

Written by Customer Service on February 12, 2025. Posted in Mergers And Acquisitions.

Calls on Beacon to Remove Shareholder-Unfriendly Poison Pill GREENWICH, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) — QXO, Inc. (NYSE: QXO) announced today that it has obtained antitrust clearance in both the U.S. and Canada for its acquisition of Beacon Roofing Supply, Inc. (Nasdaq: BECN), paving the way for QXO to close the transaction quickly. The company confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired and that it has received early termination of the waiting period from the Canadian Competition Bureau. “With committed financing in place and these necessary regulatory approvals secured, QXO is prepared to complete this acquisition and deliver immediate, compelling value to Beacon shareholders,” said Brad Jacobs, chairman and chief executive officer of QXO. “Beacon should remove...

Eminent Closes Acquisition of Celts Project in Nevada

Written by Customer Service on February 12, 2025. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Feb. 12, 2025 (GLOBE NEWSWIRE) — Eminent Gold Corp. (TSXV: EMNT) (OTCQB: EMGDF) (the “Company” or “Eminent“) is pleased to announce that, pursuant to a purchase agreement (the “Purchase Agreement”) among the Company, Hot Springs Resources Corp., a wholly owned subsidiary of the Company (“Hot Springs”), Renaissance Exploration Inc., a wholly owned indirect subsidiary of Orogen Royalties Inc. (“Orogen”) and Altius Resources Inc. (“Altius” and, together with Orogen, the “Sellers”) previously announced on December 12, 2024, the Company has completed its acquisition of the Celts mineral property (the “Celts Project“) in Nevada, USA, from the Sellers for an aggregate purchase price of US$400,000 (the “Acquisition”). Following completion of the Acquisition, the Company holds a...

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Written by Customer Service on February 12, 2025. Posted in Earnings Releases And Operating Results.

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. “We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer’s disease with convenient oral dosing with potential clinical meaningful benefit,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We are excited to...

Day: February 12, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals